{
    "root": "5a3dbd4a-e02f-4ca5-b23f-9e5c62585e9d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Mercaptopurine",
    "value": "20250221",
    "ingredients": [
        {
            "name": "MERCAPTOPURINE",
            "code": "E7WED276I5"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        }
    ],
    "indications": "mercaptopurine tablets nucleoside metabolic inhibitor indicated treatment adult pediatric patients acute lymphoblastic leukemia ( ) part combination chemotherapy maintenance regimen . ( 1.1 )",
    "contraindications": "• recommended starting dose mercaptopurine tablets 1.5 mg/kg 2.5 mg/kg orally daily part combination chemotherapy maintenance regimen . adjust dose maintain desirable absolute neutrophil count excessive myelosuppression . ( 2.1 ) • renal impairment : lowest recommended starting dose increase dosing interval . ( 2.3 , 8.6 ) • hepatic impairment : lowest recommended starting dose . ( 2.3 , 8.7 )",
    "warningsAndPrecautions": "mercaptopurine tablets , usp available containing 50 mg mercaptopurine , usp . 50 mg tablets off-white light yellow , round , scored tablets debossed score 547 score one side tablet blank side . available follows : ndc 0378-3547-52bottles 25 tablets ndc 0378-3547-25bottles 250 tablets store 20° 25°c ( 68° 77°f ) . [ usp controlled room temperature . ] protect moisture . dispense tight , light-resistant container defined usp using child-resistant closure . mercaptopurine tablets cytotoxic . follow special handling disposal procedures .",
    "adverseReactions": "none .",
    "indications_original": "Mercaptopurine tablets are a nucleoside metabolic inhibitor indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. ( 1.1 )",
    "contraindications_original": "• The recommended starting dose of mercaptopurine tablets is 1.5 mg/kg to 2.5 mg/kg orally once daily as part of a combination chemotherapy maintenance regimen. Adjust dose to maintain desirable absolute neutrophil count and for excessive myelosuppression. ( 2.1 ) • Renal Impairment : Use the lowest recommended starting dose or increase the dosing interval. ( 2.3 , 8.6 ) • Hepatic Impairment : Use the lowest recommended starting dose. ( 2.3 , 8.7 )",
    "warningsAndPrecautions_original": "Mercaptopurine Tablets, USP are available containing 50 mg of mercaptopurine, USP.\n                  The 50 mg tablets are off-white to light yellow, round, scored tablets debossed with M above the score and 547 below the score on one side of the tablet and blank on the other side. They are available as follows:\n                  NDC 0378-3547-52bottles of 25 tablets\n                  NDC 0378-3547-25bottles of 250 tablets\n                  \n                     Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]\n                  \n                  \n                     Protect from moisture.\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.\n                  Mercaptopurine tablets are a cytotoxic drug. Follow special handling and disposal procedures.",
    "adverseReactions_original": "None."
}